WallStreetZenWallStreetZen

NASDAQ: LEGN
Legend Biotech Corp Stock

$56.09-0.84 (-1.48%)
Updated Mar 28, 2024
LEGN Price
$56.09
Fair Value Price
N/A
Market Cap
$10.20B
52 Week Low
$44.52
52 Week High
$77.32
P/E
-19.08x
P/B
8.15x
P/S
37.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$285.14M
Earnings
-$518.25M
Gross Margin
49.4%
Operating Margin
-174.76%
Profit Margin
-181.8%
Debt to Equity
0.48
Operating Cash Flow
-$439M
Beta
0.84
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

LEGN Overview

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LEGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LEGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LEGN is poor value based on its book value relative to its share price (8.15x), compared to the US Biotechnology industry average (6.21x)
P/B vs Industry Valuation
LEGN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LEGN due diligence checks available for Premium users.

Be the first to know about important LEGN news, forecast changes, insider trades & much more!

LEGN News

Valuation

LEGN fair value

Fair Value of LEGN stock based on Discounted Cash Flow (DCF)
Price
$56.09
Fair Value
-$65.25
Undervalued by
185.96%
LEGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LEGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-19.08x
Industry
14.26x
Market
44.51x

LEGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.15x
Industry
6.21x
LEGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LEGN's financial health

Profit margin

Revenue
$79.5M
Net Income
-$144.8M
Profit Margin
-182.2%
LEGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LEGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.8B
Liabilities
$597.2M
Debt to equity
0.48
LEGN's short-term assets ($1.50B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LEGN's short-term assets ($1.50B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LEGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LEGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$110.0M
Investing
$237.6M
Financing
-$412.6M
LEGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LEGN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
LEGN$10.20B-1.48%-19.08x8.15x
UTHR$10.81B-5.57%10.92x1.81x
TECH$11.06B+1.40%49.92x5.64x
ASND$8.72B+1.84%-16.44x-55.68x
ROIV$8.49B-2.77%1.90x1.39x

Legend Biotech Stock FAQ

What is Legend Biotech's quote symbol?

(NASDAQ: LEGN) Legend Biotech trades on the NASDAQ under the ticker symbol LEGN. Legend Biotech stock quotes can also be displayed as NASDAQ: LEGN.

If you're new to stock investing, here's how to buy Legend Biotech stock.

What is the 52 week high and low for Legend Biotech (NASDAQ: LEGN)?

(NASDAQ: LEGN) Legend Biotech's 52-week high was $77.32, and its 52-week low was $44.52. It is currently -27.46% from its 52-week high and 25.99% from its 52-week low.

How much is Legend Biotech stock worth today?

(NASDAQ: LEGN) Legend Biotech currently has 363,822,069 outstanding shares. With Legend Biotech stock trading at $56.09 per share, the total value of Legend Biotech stock (market capitalization) is $10.20B.

Legend Biotech stock was originally listed at a price of $37.00 in Jun 5, 2020. If you had invested in Legend Biotech stock at $37.00, your return over the last 3 years would have been 51.59%, for an annualized return of 14.88% (not including any dividends or dividend reinvestments).

How much is Legend Biotech's stock price per share?

(NASDAQ: LEGN) Legend Biotech stock price per share is $56.09 today (as of Mar 28, 2024).

What is Legend Biotech's Market Cap?

(NASDAQ: LEGN) Legend Biotech's market cap is $10.20B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Legend Biotech's market cap is calculated by multiplying LEGN's current stock price of $56.09 by LEGN's total outstanding shares of 363,822,069.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.